文献速递临床试验与 GCP基础与转化研究

抗坏血酸、皮质类固醇与硫胺素联合治疗对脓毒性休克器官损伤的影响:ACTS随机临床试验

Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项多中心随机双盲试验纳入205例脓毒性休克成人患者,比较抗坏血酸、氢化可的松和硫胺素联合治疗与安慰剂对器官损伤的影响。结果显示,联合治疗未显著降低72小时内SOFA评分变化,肾衰竭发生率和30天死亡率也无显著差异。结论不支持对该组合疗法进行常规使用。

要点

  • 联合治疗组与安慰剂组72小时SOFA评分变化无显著差异。
  • 肾衰竭发生率与30天死亡率在两组间均无统计学显著差异。
  • 最常见严重不良事件为高血糖、高钠血症和医院获得性感染。

核心结论

  • 在脓毒性休克患者中,抗坏血酸、皮质类固醇和硫胺素联合治疗与安慰剂相比,未显著减少入组后72小时内的SOFA评分。
  • 这些数据不支持对脓毒性休克患者常规使用该联合疗法。

研究设计与样本

  • 随机、盲法、多中心临床试验,在美国14个中心纳入205例成人脓毒性休克患者,2018年2月9日至2019年10月27日入组,随访至2019年11月26日。
  • 干预组(n=103)每6小时接受肠外抗坏血酸1500 mg、氢化可的松50 mg和硫胺素100 mg,持续4天;安慰剂组(n=102)接受相同时间点的匹配体积安慰剂。
  • 200例(98%)接受至少1剂研究药物并纳入分析(干预组101例,安慰剂组99例)。

主要发现

  • 最常见严重不良事件:高血糖(干预组12例 vs 安慰剂组7例)、高钠血症(11例 vs 7例)、新发医院获得性感染(13例 vs 12例)。

关键数值与推荐

  • 主要结局为入组至72小时SOFA评分变化(范围0-24,0为最佳)。
  • 关键次要结局包括肾衰竭和30天死亡率。

临床怎么用

  • 不推荐对脓毒性休克患者常规使用抗坏血酸、皮质类固醇和硫胺素联合治疗。
  • 临床决策应基于现有指南和患者个体情况,不因本试验结果改变标准治疗。

局限性

  • 样本量205例,可能不足以检测较小但具有临床意义的差异。
  • 干预持续时间仅4天,长期结局未评估。
  • 研究在美国14个中心进行,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The combination of ascorbic acid, corticosteroids, and thiamine has been identified as a potential therapy for septic shock. OBJECTIVE: To determine whether the combination of ascorbic acid, corticosteroids, and thiamine attenuates organ injury in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS: Randomized, blinded, multicenter clinical trial of ascorbic acid, corticosteroids, and thiamine vs placebo for adult patients with septic shock. Two hundred five patients were enrolled between February 9, 2018, and October 27, 2019, at 14 centers in the United States. Follow-up continued until November 26, 2019. INTERVENTIONS: Patients were randomly assigned to receive parenteral ascorbic acid (1500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days (n = 103) or placebo in matching volumes at the same time points (n = 102). MAIN OUTCOMES AND MEASURES: The primary outcome was change in the Sequential Organ Failure Assessment (SOFA) score (range, 0-24; 0 = best) between enrollment and 72 hours. Key secondary outcomes included kidney failure and 30-day mortality. Patients who received at least 1 dose of study drug were included in analyses. RESULTS: Among 205 randomized patients (mean age, 68 [SD, 15] years; 90 [44%] women), 200 (98%) received at least 1 dose of study drug, completed the trial, and were included in the analyses (101 with intervention and 99 with placebo group). Overall, there was no statistically significant interaction between time and treatment group with regard to SOFA score over the 72 hours after enrollment (mean SOFA score change from 9.1 to 4.4 [-4.7] points with intervention vs 9.2 to 5.1 [-4.1] points with placebo; adjusted mean difference, -0.8; 95% CI, -1.7 to 0.2; P = .12 for interaction). There was no statistically significant difference in the incidence of kidney failure (31.7% with intervention vs 27.3% with placebo; adjusted risk difference, 0.03; 95% CI, -0.1 to 0.2; P = .58) or in 30-day mortality (34.7% vs 29.3%, respectively; hazard ratio, 1.3; 95% CI, 0.8-2.2; P = .26). The most common serious adverse events were hyperglycemia (12 patients with intervention and 7 patients with placebo), hypernatremia (11 and 7 patients, respectively), and new hospital-acquired infection (13 and 12 patients, respectively). CONCLUSIONS AND RELEVANCE: In patients with septic shock, the combination of ascorbic acid, corticosteroids, and thiamine, compared with placebo, did not result in a statistically significant reduction in SOFA score during the first 72 hours after enrollment. These data do not support routine use of this combination therapy for patients with septic shock. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03389555.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Moskowitz A, Huang DT, Hou PC, et al. Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial. JAMA. 2020. PMID: 32809003. doi:10.1001/jama.2020.11946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。